文献速递临床微生物质量管理与危急值

新型ETEST磷霉素药敏试验的多中心评估

Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species.
PubMed 文献 · J Clin Microbiol · 2022-06-23

该多中心研究评估了新型ETEST磷霉素试条对152株粪肠球菌、100株葡萄球菌和330株肠杆菌目的药敏性能,以CLSI和EUCAST琼脂稀释法为参考。参照FDA标准,大肠埃希菌基本一致率91.0%、分类一致率99.0%;粪肠球菌基本一致率98.0%、分类一致率93.4%,无重大误差。参照EUCAST静脉磷霉素折点,肠杆菌目和葡萄球菌属基本一致率分别为91.5%和94.0%,分类一致率均为98.0%。

要点

  • ETEST磷霉素对大肠埃希菌和粪肠球菌性能满足FDA标准。
  • 肠杆菌目和葡萄球菌属按EUCAST静脉折点满足ISO接受标准。
  • 肠杆菌目重大误差率8.8%,但MIC均在基本一致范围内。

核心结论

  • 新型ETEST磷霉素试条性能良好,可作为经典琼脂稀释法的替代工具。

研究设计与样本

  • 多中心研究,三个研究中心共评估152株粪肠球菌、100株葡萄球菌和330株肠杆菌目,以CLSI和EUCAST琼脂稀释法为参考方法。

主要发现

  • 参照FDA标准,大肠埃希菌基本一致率91.0%、分类一致率99.0%。
  • 粪肠球菌基本一致率98.0%、分类一致率93.4%,无重大误差和极大误差。
  • 参照EUCAST静脉磷霉素折点,肠杆菌目和葡萄球菌属基本一致率分别为91.5%和94.0%,分类一致率均为98.0%。
  • 肠杆菌目重大误差率为8.8%,但相关MIC均在基本一致范围内。
  • 观察到对柠檬酸杆菌属、大肠埃希菌和肠道沙门菌预测MIC偏低的趋势,对肺炎克雷伯菌预测MIC偏高的趋势。

关键数值与推荐

  • 大肠埃希菌:基本一致率91.0%,分类一致率99.0%(FDA标准)。
  • 粪肠球菌:基本一致率98.0%,分类一致率93.4%,无重大误差和极大误差。
  • 肠杆菌目:基本一致率91.5%,分类一致率98.0%,重大误差率8.8%(EUCAST静脉折点)。
  • 葡萄球菌属:基本一致率94.0%,分类一致率98.0%(EUCAST静脉折点)。

临床怎么用

  • 可用于肠杆菌目、粪肠球菌和葡萄球菌属的磷霉素药敏试验,替代琼脂稀释法。
  • 不应用于阴沟肠杆菌,因基本一致率低且重大误差率高。
  • 解读柠檬酸杆菌属、大肠埃希菌、肠道沙门菌和肺炎克雷伯菌结果时需注意MIC预测偏差趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fosfomycin is a phosphonic acid derivative active against a wide spectrum of Gram-positive and Gram-negative pathogens. It is used for the treatment of uncomplicated urinary tract infections (uUTI) or severe infections by oral or intravenous (i.v.) administration. In order to improve its performance and robustness, the fosfomycin strip, an antibiotic gradient diffusion strip, was redeveloped and evaluated in the multicenter study summarized in this paper. ETEST fosfomycin (ETEST FO) clinical performance was evaluated by three study sites on 152 Enterococcus faecalis, 100 Staphylococcus spp. and 330 Enterobacterales in comparison with the CLSI and EUCAST agar dilution reference method. Referring to FDA performance criteria, the ETEST FO achieved 91.0% of essential (EA) and 99.0% of categorical agreement (CA) for Escherichia coli. In addition, 98.0% EA and 93.4% CA were achieved for E. faecalis, with no very major errors (VME) or major errors (ME). According to EUCAST breakpoints for intravenous fosfomycin use, Enterobacterales and Staphylococcus spp. also met ISO acceptance criteria for EA and CA (EA 91.5%, 94.0%, respectively, and CA 98.0% for both). A VME rate of 8.8% was observed for Enterobacterales but the MICs were within EA. A trend to predict lower MICs for Citrobacter spp., E. coli and Salmonella enterica and to predict higher MICs for Klebsiella pneumoniae MICs was observed, while ETEST FO should not be used for Enterobacter cloacae, because of low EA and a high VME rate. The study results support the efficiency of the novel ETEST FO, making it an easy-to-handle tool as a substitute to the classical agar dilution method.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Goer A, Blanchard LS, Van Belkum A, et al. Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species. J Clin Microbiol. 2022. PMID: 35736011. doi:10.1128/jcm.00021-22

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。